Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Learn more about:
Related Clinical Trial
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer Metabolic Stress-induced Exercise to Prevent Loss of Muscle Mass in Patients With Pancreatic and Biliary Tract Cancer The Registry of Genetic Alterations of Taiwan Biliary Tract Cancer A Study of ABL001 in Combination With Irinotecan or Paclitaxel in Patients With Advanced or Metastatic Solid Tumors Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy Predicting Disease Progression and/or Recurrence in Cancer Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis A Phase 1/2 Study of SC-43 in Combination With Cisplatin The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Unresectable Biliary Tract Cancer. A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer A Trial of SHR1258 in Patients With Biliary Tract Cancer Perception Prognosis, Goals of Treatment, and Communication IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors Tremelimumab With Chemoembolization or Ablation for Liver Cancer Preoperative Nutritional Support in Malnutritional Cancer Patients Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery SOX Sequential S-1 in Advanced Biliary Tract Carcinoma(BTC)and Pancreatic Cancer Effect of Early Management on PAin and DEpression in Patients With PancreatoBiliary Cancer, EPADE-PB Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures. Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions Early Palliative Care on Quality of Life of Advanced Cancer Patients Patient Activation Through Counseling, Exercise and Mobilization Extracellular RNA Markers of Liver Disease and Cancer X-MAS Biliary Study With Covered Biliary Stent A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers A Prospective Cohort Study of Patients With Hepatobiliary Cancer Treated With Immune Checkpoint Inhibitors GTX Regimen for Biliary Cancers Phase II Study of Gemcitabine and TS-1 in Biliary Trat Cancer A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer FOLFIRINOX for 2nd-line Treatment of BTC Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Trastuzumab in HER2-positive Biliary Tract Cancer Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase Second Line Therapy in Advanced Biliary Tract Cancer Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer Randomized Phase 2 Study With Gemcitabine Alone and Combination Therapy for Patients With Advanced Biliary Tract Cancer A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer A Study of RC48 in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer. Case Series Study of Biliary Tract Cancer Patients in Japan GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer Molecular Profiling of Advanced Biliary Tract Cancers MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer Allogeneic NK Cell (“SMT-NK”) in Combination With Pembrolizumab in Advanced Biliary Tract Cancer Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer Vessel Resection and Reconstruction of Biliary Tract Cancers Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) NGS as the First-line Treatment in Advanced Biliary Tract Cancer Identification of Prognostic Gene Mutations in Biliary Tract Cancer Using Whole Genome Sequencing NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer Molecular Profiling of Advanced Biliary Tract Cancers

Brief Title

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

Official Title

A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

Brief Summary

      NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in
      patients with previously untreated advanced biliary tract cancer.

      The primary hypotheses are:

        -  The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the
           gemcitabine plus cisplatin standard of care

        -  The combination of NUC-1031 plus cisplatin increases overall response rate compared to
           the gemcitabine plus cisplatin standard of care
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Overall survival (OS)

Secondary Outcome

 Progression-free survival (PFS)

Condition

Biliary Tract Cancer

Intervention

NUC-1031

Study Arms / Comparison Groups

 A - NUC-1031 and cisplatin
Description:  725 mg/m^2 NUC-1031 administered in combination with 25 mg/m^2 cisplatin on Days 1 and 8 of a 21-day cycle

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

828

Start Date

December 24, 2019

Completion Date

December 2023

Primary Completion Date

December 2023

Eligibility Criteria

        Inclusion Criteria:

          1. Written informed consent and authorization to use and disclose health information.

          2. Ability to comprehend and willingness to comply with the requirements of this
             protocol, including the QoL questionnaires.

          3. Female or male patients aged ≥18 years.

          4. Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract
             (including gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers)
             that is locally advanced, unresectable or metastatic (AJCC edition 8, 2018). Patients
             with measurable (as per RECIST v1.1 criteria) or non-measurable disease are permitted.

          5. Life expectancy ≥16 weeks.

          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          7. Adequate biliary drainage with no evidence of ongoing infection. If applicable,
             treatable and clinically-relevant biliary duct obstruction has been relieved by
             internal endoscopic drainage/stenting at least 2 weeks previously or by palliative
             bypass surgery or percutaneous drainage prior to study treatment, and the patient has
             no active or suspected uncontrolled infection. Patients fitted with a biliary stent
             should be clinically stable and free of signs of infection for ≥2 weeks prior to study
             treatment. Patients with improving biliary function who meet all other inclusion
             criteria may be re-tested during the screening window.

          8. Adequate bone marrow, hepatic, and renal function, as evidenced by:

               -  Absolute neutrophil count (ANC) ≥1,500/μL without colony-stimulating factor
                  support

               -  Platelet count ≥100,000/μL

               -  Haemoglobin ≥9 g/dL without need for haematopoietic growth factor or transfusion
                  support in prior 2 weeks

               -  Total bilirubin <2 × upper limit of normal (ULN); does not apply to patients with
                  Gilbert's syndrome. Consistent with inclusion criterion 7, patients whose whole
                  bilirubin and biliary function is recovering may be re-tested during the
                  screening period.

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) <5 × ULN

               -  Creatinine clearance ≥45 mL/min actual or calculated by the Cockcroft-Gault
                  method

               -  International normalized ratio (INR) <1.5 and activated partial thromboplastin
                  time (aPTT) <1.5 × ULN; does not apply to patients on an anti-coagulant with
                  stable dose 28 days prior to first dose.

          9. QTc interval <450 msec (males) or <470 msec (females), in the absence of bundle branch
             block. In the presence of bundle branch block with consequent QTc prolongation,
             patients may be enrolled based on a careful risk-benefit assessment.

         10. Human Immunodeficiency Virus-infected patients who are healthy and have a low risk of
             Acquired Immunodeficiency Syndrome-related outcomes may be included in this study.

         11. Female patients of child-bearing potential (i.e., all women except those who are
             post-menopausal for ≥1 year or who have a history of hysterectomy or surgical
             sterilization) must have a negative pregnancy test within 3 days prior to the first
             study drug administration. All patients of child-bearing potential must agree to
             practice true abstinence or to use two highly effective forms of contraception, one of
             which must be a barrier method of contraception, from the time of screening until 6
             months after the last dose of study medication.

         12. Male patients with a female partner must either have had a successful vasectomy or
             they and their female partner meet the criteria above (not of childbearing potential
             or practicing highly effective contraceptive methods).

        Exclusion Criteria:

          1. Combined or mixed hepatocellular/cholangiocarcinoma.

          2. Prior systemic therapy for advanced or metastatic biliary tract cancer. However, prior
             chemotherapy in the adjuvant setting or low-dose chemotherapy given in conjunction
             with radiotherapy in the adjuvant setting and completed at least 6 months prior to
             enrolment is permitted. The following prior interventions are allowed provided the
             patient has fully recovered:

               -  Surgery: non-curative resection with macroscopic residual disease or palliative
                  bypass surgery. Patients who have previously undergone curative surgery must now
                  have evidence of non-resectable disease requiring systemic chemotherapy.

               -  Radiotherapy: prior radiotherapy (with or without radio-sensitizing low-dose
                  chemotherapy) for localized disease and there is now clear evidence of disease
                  progression requiring systemic chemotherapy.

               -  Photodynamic therapy: prior photodynamic therapy for localized disease with no
                  evidence of metastatic disease or for localized disease to relieve biliary
                  obstruction in the presence of metastatic disease provided there is now clear
                  evidence of disease progression requiring systemic chemotherapy.

               -  Palliative radiotherapy: palliative radiotherapy provided that all adverse events
                  have resolved and the patient has measurable disease outside the field of
                  radiation.

          3. Prior treatment with or known hypersensitivity to NUC-1031, gemcitabine, cisplatin or
             other platinum-based agents or history of allergic reactions attributed to any
             parenteral excipients (e.g. dimethylacetamide [DMA], Cremophor EL, Polysorbate 80,
             Solutol HS 15).

          4. Symptomatic central nervous system or leptomeningeal metastases.

          5. History of other malignancies, except adequately treated non-melanoma skin cancer,
             curatively treated in situ cancer of the cervix, surgically excised or potentially
             curatively treated ductal carcinoma in situ of the breast, or low grade prostate
             cancer or patients after prostatectomy not requiring treatment. Patients with previous
             invasive cancers are eligible if treatment was completed more than 3 years prior to
             initiating the current study treatment, and the patient has had no evidence of
             recurrence since then.

          6. Concurrent serious (as deemed by the Investigator) medical conditions, including, but
             not limited to, New York Heart Association class III or IV congestive heart failure,
             history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis
             B or C, or other co-morbid conditions that in the opinion of the Investigator would
             impair study participation or cooperation.

          7. Congenital or acquired immunodeficiency (e.g., serious active infection with HIV). As
             per inclusion criterion 10, patients with HIV who are healthy and have a low risk of
             AIDS related outcomes are eligible.

          8. Other acute or chronic medical, neurological, or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the Investigator, would make the patient
             inappropriate for entry into this study.

          9. Prior exposure to another investigational agent within 28 days prior to randomization.

         10. Major surgery within 28 days prior to randomization; patient must have completely
             recovered from any prior surgical or other procedures.

         11. Pregnant or breastfeeding.

         12. Residual toxicities from prior treatments or procedures which have not regressed to
             Grade ≤1 severity (CTCAE v5.0), except for alopecia or ≤ Grade 2 peripheral
             neuropathy.

         13. Concomitant use of drugs at doses known to cause clinically relevant prolongation of
             QT/QTc interval.

         14. Administration of a live vaccination within 28 days prior to randomization.

         15. Ongoing or recent (≤6 months) hepatorenal syndrome.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Jennifer Knox, MD, +44 131 357 3950, [email protected]

Location Countries

Australia

Location Countries

Australia

Administrative Informations


NCT ID

NCT04163900

Organization ID

NuTide:121

Secondary IDs

2019-001025-28

Responsible Party

Sponsor

Study Sponsor

NuCana plc


Study Sponsor

Jennifer Knox, MD, Principal Investigator, Professor of Medicine, University of Toronto


Verification Date

September 2021